#bsabs
Bispecific antibodies (BsAbs) have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously. If you are interested in learning about them, you can read all this and more here:
• pmc.ncbi.nlm.nih.gov/articles/PMC...
November 6, 2026 at 11:15 PM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy.
doi.org/10.1093/abt/...
#bispecific #bispecificantibody #bispecificantibodies #bsab #bsabs #tcellengagers #cd3 #mab
October 30, 2026 at 2:05 PM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy.
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #bsab #bsabs #VEGF #AK112
October 28, 2026 at 1:48 PM
Congratulations to Serene Chen and Wei Zhang. Your 2021 paper in our journal @antibodytx.bsky.social has received 100 citations, and is officially "famous" according to the definition of my late graduate advisor Alan Marshall. Welcome to the elite club!

doi.org/10.1093/abt/...
Current trends and challenges in the downstream purification of bispecific antibodies
ABSTRACT. Bispecific antibodies (bsAbs) represent a highly promising class of biotherapeutic modality. The downstream processing of this class of antibodie
doi.org
October 21, 2026 at 5:34 AM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Structure and function of therapeutic antibodies approved by the US FDA in 2024.
doi.org/10.1093/abt/... #biologics #bispecific #bispecificantibodies #bsab #bsabs #FDA
October 7, 2026 at 5:04 PM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy.
doi.org/10.1093/abt/...
#bispecificantibodies #bsab #bsabs #atopicdermatitis #th2cytokines #il4rα #il31rα
October 5, 2026 at 2:12 PM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication.
doi.org/10.1093/abt/...
#bispecific #bispecificantibody #bsab #bsabs #apoptosis #deathreceptor5
September 21, 2026 at 1:44 PM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight -IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy.
doi.org/10.1093/abt/...
#bispecific #bispecificantibody #bispecificantibodies #bsab #bsabs #vegf #pdl1 #adcc #adcp
September 4, 2026 at 3:31 PM
Engineered Bispecific Antibodies: Regulatory, Ethical, and Best Practice Guidelines

Immunotherapy has revolutionized cancer treatment with bispecific antibodies (BsAbs) emerging as potent therapies for hematological malignancies and certain solid cancers (Table 1). The market was valued at $12…
Engineered Bispecific Antibodies: Regulatory, Ethical, and Best Practice Guidelines
Immunotherapy has revolutionized cancer treatment with bispecific antibodies (BsAbs) emerging as potent therapies for hematological malignancies and certain solid cancers (Table 1). The market was valued at $12 billion USD in 2024 and is projected to reach $50 billion USD by 2030.1 Distinct from traditional monoclonal antibodies that target a single antigen, BsAbs possess two distinct binding domains, enabling them to concurrently target two separate antigens or different epitopes of the same antigen.2 The mechanisms and structural designs of BsAbs can be tailored to specific cancer types and patient populations with advanced antibody engineering technology.
nexttech-news.com
November 3, 2025 at 9:27 AM
February 23, 2026 at 1:37 AM
February 16, 2026 at 10:07 PM
🩸Facts about Multiple Myeloma:

Bispecific Antibodies (BsAbs) – Mechanism and Approval

#MultipleMyeloma #RRMM #Hematology #HemOnc #BispecificAntibodies #BsAbs #Immunotherapy #CD3 #BCMA #Teclistamab #Elranatamab #Linvoseltamab #MedEd
February 5, 2026 at 3:30 AM
Bispecific antibodies (BsAbs) are as #anti-cancer drugs that bridge #T-cell receptor and tumor antigens. Cryo-EM structures of BsAbs in complexes with their antigens show
domain rearrangements, resulting in major conformational changes and favorable bridging angle.

www.cell.com/cell-reports...
Bispecific antibody-antigen complex structures reveal activity enhancement by domain rearrangement
Structural insight into the bispecific antibody (BsAb) that bridges two different antigens is critical for cancer drug development. Sato et al. determine cryo-EM structures of diabody-type BsAbs in te...
www.cell.com
July 16, 2025 at 6:56 AM
Bispecifics are so in right now.

Learn more about them in this recent review: www.nature.com/articles/s41...

But now we need to understand a drug 🎯 and the immune system’s complex response modulation in its proximity
February 5, 2025 at 1:39 AM
We need to eradicate the viral reservoirs in the gut, bone marrow, and various organs, including the lungs, thymus, and more.

nature.com/articles/s41...

The virus adheres to ACE2 receptors. Can bsAbs or tsAbs dislodge it?

Sorry that you got it so bad.
Viral syncytia evolve to resist interferon - Nature Communications
Here the authors show that SARS-CoV-2 and other fusogenic viruses trade lower viral titers for interferon resistance by spreading via cell fusion rather than virion release, highlighting a benefit of ...
nature.com
July 22, 2026 at 9:52 PM
Long-term SARS-CoV-2 Persistence in Syrian Hamsters

youtube.com/shorts/SPjvf...

Viral persistence is enough to cause the inflammatory cytokines and the ongoing #LongCOVID damage.

Can a combination of mAbs, bsAbs or tsAbs engage the spikes to dislodge the viral persistence?

#medsky

#neurosky
SARS-CoV-2 RNA & protein persisted in lung, brain, and thymus for more than a year in hamsters
YouTube video by Virus Sucks
youtube.com
July 21, 2026 at 4:40 PM
Why does anyone infected with SARSCoV2 need productive replication after the acute phase when the virus is already embedded to the ACE2 receptors? Viral persistence is enough to cause the inflammatory cytokines and #LongCOVID.

Can bsAbs or tsAbs engage the spikes to dislodge the virus?
July 21, 2026 at 3:56 PM
The BSABs are just republican and Russian agents trying to generate apathy.
February 6, 2025 at 2:46 PM
Engineered Bispecific Antibodies: Regulatory, Ethical, and Best Practice Guidelines

Immunotherapy has revolutionized cancer treatment with bispecific antibodies (BsAbs) emerging as potent therapies for hematological malignancies and certain solid cancers (Table 1). The market was valued at $12…
Engineered Bispecific Antibodies: Regulatory, Ethical, and Best Practice Guidelines
Immunotherapy has revolutionized cancer treatment with bispecific antibodies (BsAbs) emerging as potent therapies for hematological malignancies and certain solid cancers (Table 1). The market was valued at $12 billion USD in 2024 and is projected to reach $50 billion USD by 2030.1 Distinct from traditional monoclonal antibodies that target a single antigen, BsAbs possess two distinct binding domains, enabling them to concurrently target two separate antigens or different epitopes of the same antigen.2 The mechanisms and structural designs of BsAbs can be tailored to specific cancer types and patient populations with advanced antibody engineering technology.
nexttech-news.com
November 3, 2025 at 9:26 AM
Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma ashpublications.org/blood/articl... #hvhebron #hemat
Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
AbstractIntroduction: Bispecific antibodies (BsAbs) are a powerful therapeutic modality in B-cell malignancies but are associated with distinct toxicities.
ashpublications.org
February 13, 2026 at 11:53 AM
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances ascopubs.org/doi/10.1200/... #hvhebron #onco
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...
ascopubs.org
April 10, 2025 at 2:11 PM
'Our recent search of data available from ClinicalTrials.gov, Cortellis and The Antibody Society revealed more than 300 clinical trials of more than 200 different bispecific molecules, with approximately 75% used to treat solid tumours and 25% to treat haematological malignancies'
The present and future of bispecific antibodies for cancer therapy - Nature Reviews Drug Discovery
Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent developments in the field of bsAbs for cancer ...
www.nature.com
April 14, 2024 at 2:28 AM
New publication 📝 Real-world data, published in Blood Advances, show BsAbs achieved superior PFS-2 (HR, 0.483) vs other therapies in patients with LBCL with late failure after CAR T-cell therapy.

Learn more:https://loom.ly/rC-uX7Y

#lymphoma #lymsm #MedNews #MedEd
December 1, 2025 at 5:30 PM